Form 4: ADMA Biologics COO Kaitlin Kestenberg-Messina Reports Share Withholding for Tax Obligations
SEC Form 4 Filing
Kaitlin Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Summary
- On April 1, 2025, Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, had 18,920 shares of common stock withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- This was not an open market sale of securities.
- Following the transaction, Kestenberg-Messina beneficially owns 490,425 shares of common stock.
- This total includes unvested RSUs granted on various dates between March 7, 2022, and February 19, 2025, which vest quarterly, as well as 188,401 shares of common stock directly owned.
Sentiment
Score: 7
Explanation: The document is a standard regulatory filing related to executive compensation. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. The sentiment is neutral to slightly positive as it reflects ongoing equity compensation.
Industry Context
This filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies. It reflects the ongoing vesting of previously granted equity awards.
Stakeholder Impact
- Shareholders are informed about executive compensation practices.
- The executive's holdings and transactions are transparently disclosed.
Key Dates
| Date | Description |
|---|---|
| 03/07/2022 | Grant date of 10,000 unvested RSUs vesting quarterly. |
| 03/06/2023 | Grant date of 47,500 unvested RSUs vesting quarterly. |
| 07/24/2023 | Grant date of 22,500 unvested RSUs vesting quarterly. |
| 04/01/2024 | Grant date of 144,240 unvested RSUs vesting quarterly. |
| 02/19/2025 | Grant date of 77,784 unvested RSUs vesting quarterly. |
| 04/01/2025 | Date of share withholding for tax obligations. |
| 04/02/2025 | Date of Form 4 filing. |
Keywords
ADMA Biologics, Kaitlin Kestenberg-Messina, Form 4, Beneficial Ownership, Restricted Stock Units, Tax Withholding, ADMA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.